Quarterly Result16 May 2025, 09:32 pm
IOL Chemicals & Pharmaceuticals Ltd. Delivers Strong Q4 Performance with 17% EBITDA and 12% PAT Growth
AI Summary
IOL Chemicals & Pharmaceuticals Ltd., one of the leading manufacturers of Pharmaceuticals & Specialty Chemicals, announced its audited financial results for the quarter and year ended 31st March 2025. The company achieved a 7% increase in revenue from operations, 17.1% growth in EBITDA, and 12.2% growth in Profit After Tax (PAT) compared to the same period last year. The operational highlights include the successful commissioning of a new Paracetamol production unit, expansion of Clopidogrel Bisulphate capacity, and securing approvals for exports to Europe and China.
Key Highlights
- Revenue from Operations increased by 4.7% Y-o-Y to 527.8 Cr in Q4 FY25
- EBITDA grew by 17.1% Y-o-Y to 67.5 Cr in Q4 FY25
- PAT increased by 12.2% Y-o-Y to 31.6 Cr in Q4 FY25
- Commissioned Unit-11 for Paracetamol at the Barnala facility with an annual capacity of 10,800 MTPA
- Expanded Clopidogrel Bisulphate capacity from 180 MTPA to 240 MTPA at Unit-5